Article

Genentech, Alcon ranked among 'best companies to work for'

Fortune magazine has released its annual list of the "100 Best Companies to Work For," with the ophthalmic industries' Genentech Inc. and Alcon Laboratories Inc. earning recognition.

Topping the list in 2006 is Genentech Inc. Placing for 8 consecutive years, the company has been dedicated to cultivating an environment where employees enjoy coming to work every day.

"I am proud of the dedication of Genentech's employees to patients and of the recognition that the company has received for being the best place to work in the country," said Herb Boyer, PhD, Genentech co-founder and board director. "This acknowledgement is a tribute to the excellent performance of the company and the leadership at Genentech."

Alcon also made the list for the eighth consecutive year. The company jumped 10 spots from 42 to 32. Fortune cited the company's comprehensive benefits package, generous compensation, and its welcoming corporate campus as some of its employee-friendly benefits.

"It is very gratifying to be recognized by Fortune as one of the best places to work," said Cary Rayment, Alcon chairman, president, and chief executive officer. "At Alcon, we strive to create a work environment that will motivate our employees and reward them for their contributions. We feel truly fortunate to have wonderful employees who are committed to our mission of advancing the preservation and enhancement of vision."

Fortune compiles the list based on two criteria-an evaluation of the policies and culture of each company and the opinions of the company's employees. Companies are scored in four areas: credibility (communication to employees), respect (opportunities and benefits), fairness (compensation, diversity), and pride/camaraderie (philanthropy, celebrations).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
© 2025 MJH Life Sciences

All rights reserved.